Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Ventilation 40% Improvement Relative Risk c19hcq.org Capsoni et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 52 patients in Italy Lower ventilation with HCQ (not stat. sig., p=0.3) Capsoni et al., Research Square, doi:10.21203/rs.3.rs-113418/v1 Favors HCQ Favors control
CPAP Treatment In COVID-19 Patients: A Retrospective Observational Study In The Emergency Department
Capsoni et al., Research Square, doi:10.21203/rs.3.rs-113418/v1 (Preprint)
Capsoni et al., CPAP Treatment In COVID-19 Patients: A Retrospective Observational Study In The Emergency Department, Research Square, doi:10.21203/rs.3.rs-113418/v1 (Preprint)
Dec 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Small 52 patient retrospective study of patients with acute respiratory failure showing lower rates of intubation with HCQ.
risk of mechanical ventilation, 40.0% lower, RR 0.60, p = 0.30, treatment 12 of 40 (30.0%), control 6 of 12 (50.0%), NNT 5.0.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Capsoni et al., 1 Dec 2020, retrospective, Italy, preprint, 13 authors, average treatment delay 7.0 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: CPAP Treatment In COVID-19 Patients: A Retrospective Observational Study In The Emergency Department Nicolò Capsoni (  nicolo.capsoni@gmail.com ) ASST Grande Ospedale Metropolitano Niguarda: Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda https://orcid.org/0000-0003-2758-4408 Daniele Privitera ASST Grande Ospedale Metropolitano Niguarda: Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda Annamaria Mazzone ASST Grande Ospedale Metropolitano Niguarda: Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda Chiara Airoldi Università degli Studi del Piemonte Orientale Amedeo Avogadro: Universita degli Studi del Piemonte Orientale Amedeo Avogadro Valentina Albertini ASST Grande Ospedale Metropolitano Niguarda: Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda Laura Angaroni ASST Grande Ospedale Metropolitano Niguarda: Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda Marta Bergamaschi ASST Grande Ospedale Metropolitano Niguarda: Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda Alberto Dal Molin Università degli Studi del Piemonte Orientale Amedeo Avogadro: Universita degli Studi del Piemonte Orientale Amedeo Avogadro Elisa Forni ASST Grande Ospedale Metropolitano Niguarda: Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda Federico Pierotti ASST Grande Ospedale Metropolitano Niguarda: Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda Eugenia Rocca Page 1/18 ASST Grande Ospedale Metropolitano Niguarda: Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda Fabrizio Vincenti ASST Grande Ospedale Metropolitano Niguarda: Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda Andrea Bellone ASST Grande Ospedale Metropolitano Niguarda: Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda Original Research Keywords: CPAP, non-invasive ventilation, COVID-19, hypoxemic respiratory failure Posted Date: November 30th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-113418/v1 License:   This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 2/18 Abstract Background During COVID-19 outbreak, with the increasing number of patients presenting with acute respiratory failure (ARF), a large use of non-invasive positive pressure ventilation (NIPPV) was done in the Emergency Departments (EDs) and medical wards despite the lack of recommendations. We aimed to assess the use of continuous positive airway pressure (CPAP) in the ED. The primary endpoint was the rate of CPAP failure and the need of endotracheal intubation (ETI). Secondary endpoints were in-hospital mortality and intensive care unit (ICU) and in-hospital length of stay. Methods A retrospective observational study enrolling adult patients admitted to the ED of Niguarda Hospital, Milan, Italy, with ARF due to COVID-19 pneumonia from March 18th to April 18th 2020, was conducted. Only patients who strictly followed a local CPAP protocol were enrolled. Results A total of 52 patients were included in this study. 38 patients (73%) were judged eligible for ETI. 18 (34.6%) were intubated. 16 (30.8%) patients died: 7 (38.9%) and 9 (26.5%) in the ETI and non-ETI group respectively. The median hospital length of stay was different in ETI and non-ETI patients: 26 days [IQR 16–37] vs 15 days..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit